VolitionRx Limited reported $1.4 million in first-half 2026 revenue, up 112% year over year, as it expanded clinical and commercial operations across sepsis, oncology and companion-animal diagnostics. Nu.Q NETs H3.1 data published in Critical Care Medicine independently predicted 28-day mortality and renal replacement therapy in sepsis, while a bedside finger-prick prototype showed clinical correlation with the company's established assay. Recruitment for France's approximately $7.3 million government-backed DETECSEPS evaluation is expected to begin in September 2026. Volition also reported that Capture-Seq detected more than 95% of Stage I and II cancers with 95% specificity, prepared a conditional French reimbursement filing for its lung-cancer test, advanced a feline lymphoma assay that could trigger a $5 million milestone upon peer-reviewed publication, transferred Nu.Q NETs to Sysmex Corporation's platform and continued discussions with more than twelve diagnostic and liquid-biopsy companies. The shares rose 100.47% to $0.68 in premarket trading, near a 52-week low of $0.32, according to Benzinga Pro data.